delafloxacin; delafloxacin meglumine (Baxdela)
Jump to navigation
Jump to search
Indications
- skin infections, including MRSA[1]
Dosage
- 300 mg IV q12hr for 5-14 days, OR
- 300 mg IV q12hr, then switch t450-mg PO q12hr for 5-14 days, OR
- 450 mg PO q12hr for 5-14 days
Mechanism of action
- fluoroquinolone antibiotic
- inhibits both bacterial topoisomerase IV & DNA gyrase (topoisomerase II)
More general terms
References
- ↑ 1.0 1.1 Lowes R FDA Approves Delafloxacin (Baxdela) for Skin Infections Medscape - Jun 19, 2017. http://www.medscape.com/viewarticle/881827
Windle ML. FDA New Drug and Biologic Approvals -- 2017 Year-in-Review Medscape - Jan 11, 2018. https://reference.medscape.com/viewarticle/890871
U.S. Food and Drug Administration. Novel Drug Approvals for 2017. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm - ↑ Baxdela (delafloxacin) prescribing information. Melinta Therapeutics, Inc. Lincolnshire, IL. June 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208610s000,208611s000lbl.pdf